This study will help determine if certain patient and practice characteristics make patients better candidates for one method over the others. Results will help fill a gap in the evidence around effectively treating OUD with MAT in primary care settings. HOMER will equip primary care practices with useful information to help provide the best care.
The three methods compared are: 1) home induction (asynchronous, unobserved), 2) office induction (synchronous, observed), and 3) telehealth induction (synchronous phone or video contact, observed).
The HOMER study is a partnership between the State Network of Colorado Ambulatory Practices and Partners (SNOCAP) and the American Academy of Family Physicians National Research Network. HOMER will work with 100 primary care practices across the country and will enroll 1200 participants.
Participants will be patients:
- Identified by their primary care team as having opioid dependence and OUD and opting to receive MAT with buprenorphine.
- Randomized to begin treatment with home induction (asynchronous, unobserved) OR office induction (synchronous, observed) OR telehealth induction (synchronous phone or video contact, observed).
- Ages 16 and older, pregnant women are also eligible.
- Enrolled begins in April 2021.
Practices will:
- Identify ~12 patients (between 6 – 20) over a 12-month period to participate.
- Receive $200 for attending a required, 90-minute study orientation webinar.
- Receive $200/enrolled patient and $35/month/patient for 9 months of monitoring and data tracking.
- Receive access to MAT resources, including treatment protocols, forms, and guidelines.
-
Begin participation in Spring/Summer 2021.
